Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.
Loughborough, England, May 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.
Chief Executive Officer Faz Chowdhury, Ph.D. will deliver his corporate presentation at 3:15pm ET on May 14, 2021.
Investors can also request a one-on-one meeting with Dr. Chowdhury to be arranged following the conclusion of the conference.
Investors can register for the conference here: https://www.benzinga.com/events/small-cap/global/
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
